Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Profit After Tax (2016 - 2025)

Kiora Pharmaceuticals' Profit After Tax history spans 11 years, with the latest figure at -$6.5 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 54.29% year-over-year to -$6.5 million; the TTM value through Dec 2025 reached -$10.8 million, down 401.42%, while the annual FY2025 figure was -$10.8 million, 401.42% down from the prior year.
  • Profit After Tax reached -$6.5 million in Q4 2025 per KPRX's latest filing, down from $26806.0 in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $13.5 million in Q1 2024 to a low of -$6.5 million in Q4 2025.
  • Average Profit After Tax over 5 years is -$2.3 million, with a median of -$2.5 million recorded in 2021.
  • Peak YoY movement for Profit After Tax: plummeted 421.44% in 2021, then skyrocketed 819.99% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$6.2 million in 2021, then increased by 17.19% to -$5.1 million in 2022, then surged by 55.69% to -$2.3 million in 2023, then plummeted by 86.17% to -$4.2 million in 2024, then tumbled by 54.29% to -$6.5 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Profit After Tax are -$6.5 million (Q4 2025), $26806.0 (Q3 2025), and -$2.2 million (Q2 2025).